Lisata Acquisition Tender Offer Commences at $4.00 Cash + CVR, Financing Still Uncommitted
LSTA sits 96% above its 52-week low of $1.81.
Summary
Kuva Labs has commenced its tender offer to acquire Lisata Therapeutics for $4.00 per share in cash plus a contingent value right (CVR) worth up to an additional $3.00 per share. This follows numerous delays and amendments to the merger agreement, including a reduction in the cash component and Lisata's previous "going concern" warning, and was also disclosed in an SC TO-T filing today. While the tender offer has finally begun, a critical detail is that Kuva Labs does not have committed financing for the acquisition, stating there is "no assurance that such financing will be obtained." This introduces significant uncertainty and risk to the deal's completion. The tender offer is set to expire on July 10, 2026, and the transaction is expected to close in Q3 2026, subject to financing and customary conditions.
At the time of this announcement, LSTA was trading at $3.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $31.5M. The 52-week trading range was $1.81 to $5.07. This news item was assessed with neutral market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.